Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 7/20 | 0.37 |
| ▸ | BRAF | P15056 | 7/20 | 0.37 |
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 2/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795819 | 1.00 | RAF1 (0.37) | RAF1BRAFMTORPIK3CAPIK3CD | |
| SCHEMBL2131260 | 0.92 | RAF1 (0.39) | RAF1BRAFMTORPIK3CAPIK3CD | |
| SCHEMBL30824705 | 0.88 | ALDH1A1 (0.42) | RAF1BRAF | |
| SCHEMBL2127971 | 0.88 | ALDH1A1 (0.42) | RAF1BRAF | |
| SCHEMBL2131112 | 0.84 | MTOR (0.38) | RAF1BRAFMTORPIK3CAPIK3C3 | |
| SCHEMBL30795047 | 0.84 | MTOR (0.38) | RAF1BRAFMTORPIK3CAPIK3C3 | |
| SCHEMBL2129803 | 0.83 | RAF1 (0.39) | RAF1BRAFMTORPIK3CAPIK3CD | |
| SCHEMBL2129268 | 0.83 | BRAF (0.41) | RAF1BRAFMTORPIK3CAPIK3CD | |
| SCHEMBL30795893 | 0.83 | BRAF (0.41) | RAF1BRAFMTORPIK3CAPIK3CD | |
| SCHEMBL2128537 | 0.82 | PIK3CD (0.37) | RAF1BRAFMTORPIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318556-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2018-05-09 | — | — | EP | claimed |
| US-20140213569-A1 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2014-07-31 | — | — | US | claimed |
| US-8552200-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-10-08 | — | — | US | claimed |
| EP-2630123-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-08-28 | — | — | EP | claimed |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-10-11 | — | — | US | claimed |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-04-26 | — | — | US | claimed |
| WO-2012052167-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-04-26 | — | — | WO | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-3318556-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2018-05-09 | — | — | EP | disclosed |
| EP-2630123-B1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-9278103-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2016-03-08 | — | — | US | disclosed |
| US-9168259-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20140213569-A1 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2014-07-31 | — | — | US | disclosed |
| US-8552200-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| EP-2630123-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| WO-2012052167-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213569-A1 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | KCNQ2, KCNQ1, KCNQ3 | RAF1 1768/4885BRAF 2192/4885MTOR 2678/4885 |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | RAF1 1768/4885BRAF 2192/4885MTOR 2678/4885 |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | RAF1 1768/4885BRAF 2192/4885MTOR 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.